Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ACT Biotech Inc
San Francisco, California, United Statesactbiotech.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
ACT Biotech is a privately held biopharmaceutical company focused on developing and commercializing targeted oral therapies for cancer. Its lead program, Telatinib—an oral kinase inhibitor targeting multiple angiogenesis-related receptors—has reached Phase II clinical trials with encouraging interim results and received Orphan Drug status from the FDA. Other pipeline assets are at earlier stages.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (oral kinase inhibitors)
- Industry
- Biotech
Beyond the preview
Go deeper on ACT Biotech Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT Biotech Inc.